


RealRate

PHARMACEUTICAL 2018



Calithera Biosciences Inc. Rank 70 of 349





PHARMACEUTICAL 2018





Calithera Biosciences Inc. Rank 70 of 349

The relative strengths and weaknesses of Calithera Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Calithera Biosciences Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 103% points. The greatest weakness of Calithera Biosciences Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 34% points.

The company's Economic Capital Ratio, given in the ranking table, is 44%, being 322% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	167,667
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	39,027
Liabilities, Non-Current	0
Other Assets	23,029
Other Compr. Net Income	-257
Other Expenses	0
Other Liabilities	3,121
Other Net Income	1,860
Property and Equipment	1,759
Research and Development	43,111
Revenues	25,955
Selling, General and Administrative Expense	12,530

Output Variable	Value in 1000 USD
Assets	192,455
Liabilities	42,148
Expenses	55,641
Stockholders Equity	150,307
Net Income	-27,826
Comprehensive Net Income	-27,954
Economic Capital Ratio	44%